Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV001288060 | SCV001474892 | uncertain significance | not provided | 2020-08-13 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004035555 | SCV003900547 | uncertain significance | not specified | 2023-02-23 | criteria provided, single submitter | clinical testing | The c.331G>A (p.V111M) alteration is located in exon 4 (coding exon 4) of the CACNB4 gene. This alteration results from a G to A substitution at nucleotide position 331, causing the valine (V) at amino acid position 111 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Solve- |
RCV004770002 | SCV005091442 | likely pathogenic | Epilepsy, idiopathic generalized, susceptibility to, 9 | 2022-06-01 | no assertion criteria provided | provider interpretation | Variant confirmed as disease-causing by referring clinical team |